Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469468 | 0.72 | MAOB (0.38) | GRM5MAPTTDP2NSD2 | |
| SCHEMBL18257983 | 0.65 | GRM5 (0.54) | GRM5MAPT | |
| SCHEMBL14741423 | 0.62 | PBRM1 (0.53) | — | |
| Hydrochloric Acid SCHEMBL4411296 | 0.62 | HTR2C (0.46) | — | |
| SCHEMBL45956 | 0.61 | — | — | |
| SCHEMBL3412400 | 0.61 | — | — | |
| SCHEMBL78498 | 0.61 | — | — | |
| SCHEMBL23649993 | 0.59 | MAP4K1 (0.39) | MAPTTDP2NSD2ALOX5PIM1 | |
| SCHEMBL23649968 | 0.59 | MAP4K1 (0.39) | MAPTTDP2NSD2ALOX5PIM1 | |
| SCHEMBL23649969 | 0.59 | MAP4K1 (0.39) | MAPTTDP2NSD2ALOX5PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | HAVCR2, HPD, CYP24A1 | GRM5 2213/4885MAPT 551/4885TDP2 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.